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Remyelination failure plays an important role in the pathophysiology of multiple sclerosis, but the underlying cellular and molecular
mechanisms remain poorly understood. We now report actively demyelinating lesions in patients with multiple sclerosis are associated
with increased glial expression of ﬁbroblast growth factor 9 (FGF9), which we demonstrate inhibits myelination and remyelination
in vitro. This inhibitory activity is associated with the appearance of multi-branched ‘pre-myelinating’ MBP+/PLP+ oligodendrocytes
that interact with axons but fail to assemble myelin sheaths; an oligodendrocyte phenotype described previously in chronically
demyelinated multiple sclerosis lesions. This inhibitory activity is not due to a direct effect of FGF9 on cells of the oligodendrocyte
lineage but is mediated by factors secreted by astrocytes. Transcriptional proﬁling and functional validation studies demonstrate that
these include effects dependent on increased expression of tissue inhibitor of metalloproteinase-sensitive proteases, enzymes more
commonly associated with extracellular matrix remodelling. Further, we found that FGF9 induces expression of Ccl2 and Ccl7, two
pro-inﬂammatory chemokines that contribute to recruitment of microglia and macrophages into multiple sclerosis lesions. These data
indicate glial expression of FGF9 can initiate a complex astrocyte-dependent response that contributes to two distinct pathogenic
pathways involved in the development of multiple sclerosis lesions. Namely, induction of a pro-inﬂammatory environment and failure
of remyelination; a combination of effects predicted to exacerbate axonal injury and loss in patients.
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Introduction
Experimental studies demonstrate the default response
to immune-mediated demyelination in the CNS is rapid
remyelination by oligodendrocytes derived from an
endogenous pool of mitotic CSPG4+ (also known as
NG2+) oligodendrocyte progenitor cells (OPCs; Tripathi
et al., 2010). However, in multiple sclerosis this repair
mechanism frequently fails resulting in chronically demye-
linated plaques of gliotic scar tissue (Franklin and Ffrench-
Constant, 2008). This has profound pathophysiological
consequences as loss of myelin not only disrupts axonal
function per se, but also compromises the physical integrity
of affected axons by increasing their susceptibility to in-
ﬂammatory mediators (Redford et al., 1997) and disrupting
trophic support provided by myelinating oligodendrocytes
(Fu¨nfschilling et al., 2012). This combination of effects will
exacerbate axonal loss in patients (Nave, 2010; Franklin
et al., 2012) and restoring endogenous remyelination is
now considered an attractive strategy to prevent further
axonal damage and restore function (Irvine and
Blakemore, 2008; Duncan et al., 2009; Deshmukh et al.,
2013). However achieving this goal in multiple sclerosis
requires a far better understanding of why remyelination
fails and how this is related to the inﬂammatory compo-
nent of the disease.
Failure of remyelination is not due to an intrinsic defect in
cells of the oligodendrocyte lineage as demonstrated by the
presence of remyelinated ‘shadow plaques’ in many patients
at autopsy (Prineas and Connell, 1979; Prineas et al., 1993;
Raine and Wu, 1993; Patrikios et al., 2006; Patani et al.,
2007). However, the efﬁcacy of this endogenous repair
mechanism declines with disease progression (Patani et al.,
2007; Goldschmidt et al., 2009). Studies in rodents suggest
this may be due to the cumulative effects of repeated or
sustained episodes of inﬂammatory demyelination on OPC
recruitment or survival (Linington et al., 1992), which will
be exacerbated by effects related to normal ageing (Shen
et al., 2008). Nonetheless in patients the mechanisms respon-
sible for failure of remyelination remain obscure. The con-
tinued presence of signiﬁcant numbers of OPCs in many
lesions suggests this involves factors that inhibit OPC differ-
entiation (Scolding et al., 1999; Chang et al., 2002;
Wolswijk, 2002; Kuhlmann et al., 2008), although effects
reducing OPC recruitment and/or survival will also impact
on remyelination efﬁcacy (Piaton et al., 2009).
Experimental studies suggest a large number of different
mechanisms are available that might inhibit OPC
differentiation and remyelination in multiple sclerosis.
These include factors affecting interactions with extracellu-
lar matrix components, altered availability of growth fac-
tors and/or OPC guidance cues or which trigger
inappropriate re-expression of developmental signalling
pathways (reviewed in Kotter et al., 2011). Convincing ar-
guments are available to support a role for each of these in
lesion development, but their relative importance with re-
spect to failure of remyelination remains unclear. Resolving
this question is important as it will determine which ef-
fector pathway(s) provide the most appropriate target for
treatment strategies designed to restore endogenous
remyelination.
One potential target is signal transduction by members of
the ﬁbroblast growth factor (FGF) family (Bansal, 2002;
Mohan et al., 2014), which play important roles in coor-
dinating neuronal and glial differentiation and survival
during CNS development (Guillemot and Zimmer, 2011).
In the context of multiple sclerosis, previous studies focused
on the possible involvement of FGF2 (Sarchielli et al.,
2008), a pleiotrophic growth factor expressed by macro-
phages and microglia in active white matter lesions
(Clemente et al., 2011). However, it is difﬁcult to deduce
the functional signiﬁcance of increased expression of FGF2,
as it can exert both potentially beneﬁcial as well as detri-
mental effects in the adult CNS. On one hand it may limit
axonal loss by virtue of its neuroprotective properties
(Rufﬁni et al., 2001; Rottlaender et al., 2011) or enhance
remyelination by supporting the expansion and speciﬁca-
tion of OPCs derived from neural stem cells (McKinnon
et al., 1990; Azim et al., 2012). However, any beneﬁt pro-
vided by these effects are thought to be negated by other
effects that may inhibit OPC differentiation and comprom-
ise remyelination (Bansal, 2002; Butt and Dinsdale, 2005;
Tobin et al., 2011; Azim et al., 2012; Mierzwa et al.,
2013). Unravelling the pathophysiological signiﬁcance of
FGF2 is complicated further by expression of other FGF
family members in the CNS that signal using the same
FGF receptor (FGFR) isoforms (Tacer et al., 2010;
Mohan et al., 2014). These include FGF9 that is expressed
constitutively by many adult neurons, and mimics the abil-
ity of FGF2 to suppress myelin protein expression by dif-
ferentiating OPCs (Cohen and Chandross, 2000); an
observation that led us to investigate whether it might
also contribute to lesion formation in multiple sclerosis.
We now report lesion formation is associated with
increased expression of ﬁbroblast growth factor 9 (FGF9)
by astrocytes and oligodendrocytes and demonstrate this
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pleiotropic growth factor inhibits myelination and remyeli-
nation in vitro. This is not due to a direct effect of FGF9 on
cells of the oligodendrocyte lineage, but is an off target
effect mediated by soluble astrocyte-derived factors that
inhibit the terminal differentiation of myelinating oligo-
dendrocytes. In tissue culture this is associated with the
appearance of multi-branched ‘pre-myelinating’ oligo-
dendrocytes that extend processes that interact with
axons, but fail to form myelin sheaths; an oligodendrocyte
phenotype reminiscent of that seen in chronically demyeli-
nated multiple sclerosis lesions (Chang et al., 2002).
Transcriptional proﬁling of myelinating cultures revealed
FGF9 modulated expression of genes involved in several
pathways identiﬁed previously as contributing to failure of
remyelination in multiple sclerosis, in particular several asso-
ciated with components of the extracellular matrix (Kotter
et al., 2011). These included effects predicted to impact on
remyelination due to altered CD44/hyaluronan signalling
(Tuohy et al., 2004; Back et al., 2005; Chang et al., 2012;
Bugiani et al., 2013), as well as increased expression of
chondroitin sulphate proteoglycans (Siebert et al., 2011)
and ﬁbronectin (Maier et al., 2005; Siskova´ et al., 2006,
2009; Stoffels et al., 2013). These changes were associated
with signiﬁcantly increased expression of mRNAs encoding
ADAMTS1 and other metalloproteases associated with
extracellular matrix remodelling. Subsequent experiments
conﬁrmed increased expression/activity of these tissue inhibi-
tors of metalloproteinases (TIMP)-sensitive proteases con-
tribute signiﬁcantly to the mechanisms by which FGF9
inhibits myelination. In addition FGF9 also induced an
innate immune signature characterized by increased astro-
cytic expression of Ccl2 and Ccl7; pro-inﬂammatory chemo-
kines that contribute to the development of inﬂammatory
responses in the CNS (Fuentes et al., 1995; Mahad and
Ransohoff, 2003; Thompson and Van Eldik, 2009; Renner
et al., 2011; Trujillo et al., 2013).
In summary our data demonstrate that FGF9 can initiate a
complex astrocytic response predicted to compromise remye-
lination, while at the same time stimulating microglial/
macrophage recruitment in multiple sclerosis lesions; a com-
bination of effects predicted to exacerbate axonal loss and
accumulation of disability in patients with progressive mul-
tiple sclerosis (Franklin et al., 2012). We suggest inhibition
of FGF-mediated signal transduction in astrocytes may pro-
vide an effective target for treatment strategies that simultan-
eously enhance endogenous remyelination and suppress
intrinsic pro-inﬂammatory responses in the CNS.
Materials and methods
Immunohistochemical analysis of
human tissues
Immunohistochemical studies were performed on archived
formalin-ﬁxed, parafﬁn-embedded brain material from
14 patients with multiple sclerosis and six controls without
neurological disease or evidence of brain lesions (Table 1).
Immunohistochemical studies were performed on consecutive
deparafﬁnized 5mm sections after endogenous peroxidase was
blocked with H2O2/methanol. Antigen retrieval was performed
using citrate buffer (pH 6.0) and non-speciﬁc antibody binding
was blocked by incubating sections in 10% foetal calf serum.
Primary antibodies to FGF9 (rabbit polyclonal, Abcam,
1:1000), carbonic anhydrase II (CAII; sheep polyclonal, The
Binding Site, 1:1000), glial ﬁbrillary acidic protein (GFAP;
mouse monoclonal; Neomarkers; 1:200) and amyloid precur-
sor protein (APP; mouse monoclonal; Chemicon, 1:1000)
were applied overnight at 4C. Antibody binding was
routinely visualized using appropriate species-speciﬁc horse
radish peroxidase conjugated secondary antibodies and 3,3’-
diaminobenzidine (DAB). Cell nuclei were counterstained with
haematoxylin before mounting.
Fluorescence double immunostainings were successfully per-
formed on biopsy tissue from ﬁve patients with early active
demyelinating lesions using anti-FGF9 (Abcam, 1:400), anti-
NogoA (11C7, 1:4000, kindly provided by Martin Schwab,
University and ETH Zurich, Switzerland) and anti-GFAP
(Dako, mouse monoclonal; 1:300) antibodies, respectively.
Anti-rabbit-Cy3 (1:200) and anti-mouse-Alexa Fluor 488
(1:500) secondary antibodies were used to detect bound pri-
mary antibodies. Sections were counterstained with DAPI
(40,6-diamidino-2-phenylindole). The density of FGF9 immu-
noreactive astrocytes was determined using an ocular morpho-
metric grid at a magniﬁcation of 400. Demyelinating lesion
areas as well as periplaque tissue (3/5) and normal-appearing
white or grey matter (3/5) were available for analysis.
Astrocytes were identiﬁed by virtue of their nuclear and cyto-
plasmic morphology. The percentage of FGF9-immunoreactive
astrocytes was determined for lesion and periplaque tissue.
Cell culture
Dissociated myelinating cultures were generated as described
previously (Elliott et al., 2012). Brieﬂy, neurospheres were gen-
erated from striata of post-natal Day 1 Sprague-Dawley rats
by resuspending dissociated cells in 20ml neurosphere media
[Dulbecco’s modiﬁed Eagle medium (DMEM)/F12 (1:1,
DMEM containing 4500mg/l glucose), supplemented with
0.105% NaHCO3, 2mM glutamine, 5000 IU/ml penicillin,
5 mg/ml streptomycin, 5.0mM HEPES, 0.0001% bovine
serum albumin, (all from Invitrogen), 25 mg/ml insulin,
100 mg/ml apotransferrin, 60 mM putrescine, 20 nM progester-
one, and 30 nM sodium selenite (all from Sigma)] and plating
them in a 75 cm3 tissue culture ﬂask. The culture was supple-
mented with 20 ng/ml mouse submaxillary gland epidermal
growth factor (R&D Systems), and maintained at 37C in a
humidiﬁed atmosphere of 7% CO2/93% air. Every 2–3 days,
5ml neurosphere medium and 4ml EGF were added to
the ﬂask. Neurosphere-derived astrocytes were obtained by
triturating neurospheres and plating them onto poly-L-lysine
(13 mg/ml) coated cover slips (13-mm diameter, VWR
International) in low glucose DMEM supplemented with
10% foetal bovine serum and 2mM L-glutamine (Sigma)
until they formed a conﬂuent monolayer.
Neurosphere-derived astrocytes conditioned media was
obtained from conﬂuent neurosphere-derived astrocyte mono-
layers grown in differentiation medium without insulin
(see below) in the presence or absence of 100 ng/ml FGF9
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for 3 days. These supernatants were immediately used to treat
myelinating cultures (3:1 vol/vol supernatant/fresh differenti-
ation medium without insulin) from 18 to 28 days in vitro
(DIV) in the presence or absence of a neutralizing antibody
speciﬁc for human FGF9 (R&D Systems, 10 mg/ml).
Myelinating spinal cord cultures were derived from embry-
onic Day 15.5 Sprague-Dawley embryos. Spinal cords were
dissected out, meninges removed, minced with a scalpel
blade and enzymatically dissociated with 2.5% trypsin
(Invitrogen) and 1.33% collagenase (ICN Pharmaceuticals).
Enzymatic activity was stopped by adding 1ml of a solution
containing 0.52mg/ml soybean trypsin inhibitor, 3.0mg/ml
bovine serum albumin, and 0.04mg/ml DNase (Sigma). The
tissue was then triturated, centrifuged and resuspended in plat-
ing medium [50% DMEM, 25% horse serum, 25% Hank’s
Balanced Salt Solution (HBSS)], and thereafter 150 000 cells in
50 ml were plated on cover slips coated with a conﬂuent mono-
layer of neurosphere-derived astrocytes. Coverslips were placed
in 35mm Petri dishes (three per dish) and left in the incubator
to attach for 2 h, and subsequently 450ml of plating medium
and 600ml of differentiation medium [DMEM (4500mg/ml
glucose), 10 ng/ml biotin, 0.5% hormone mixture (1mg/ml
apotransferrin, 20mM putrescine, 4mM progesterone, and
6 mM selenium; formulation based on Bottenstein and Sato,
1979), 50 nM hydrocortisone, and 0.1 mg/ml insulin (all re-
agents from Sigma)] was added. Every 2 days 500 ml of
media was withdrawn and replaced by fresh differentiation
media. From 12 DIV onwards cultures were fed with insulin
free differentiation medium. The effect of recombinant human
FGF9 and other soluble factors (all obtained from R&D
Systems) on myelinating cultures was investigated between
18 and 28 DIV. To block proliferation, cultures were treated
with 20 mM cytosine b-D-arabinofuranoside (AraC, Sigma).
ADAMTS and matrix metalloproteinase (MMP) activity was
inhibited by adding a cocktail containing 3mg/ml recombinant
human tissue inhibitor of MMP1, MMP2 and MMP3 (TIMP1,
TIMP2 and TIMP3; all from R&D Systems).
A2B5+ OPCs were isolated from post-natal Day 1 rat
cortex. Brieﬂy, meninges were removed and tissue digested
with a neural tissue dissociation kit containing Papain
(Miltenyi Biotec) according to the manufacturer’s instructions.
Tissue was digested for 25min at 37C and then dissociated
manually to give a single cell suspension. Cells were centri-
fuged at 300 g for 10min, after which OPCs were puriﬁed
by MACS magnetic bead separation using anti-A2B5
MicroBeads (Miltenyi Biotec). A2B5+ cells were resuspended
in Basal Chemically Deﬁned medium [DMEM, 4mM
L-glutamine, 1mM sodium pyruvate, 0.1% bovine serum
albumin (BSA), 50mg/ml apo-transferrin, 5 mg/ml insulin,
30 nM sodium selenite, 10 nM D-biotin and 10 nM hydrocor-
tisone] containing 20 ng/ml PDGF-AA and 20 ng/ml FGF2 and
plated on poly-L-lysine (13 mg/ml) coated coverslips at a dens-
ity of 1–2  104 cells/cm2. After 3 DIV PDGF/FGF2 was with-
drawn and cells were allowed to differentiate for up to 7 days
in modiﬁed Sato’s medium (Bottenstein and Sato, 1979;
DMEM containing 4500mg/l glucose, 2mM glutamine,
5000 U/ml penicillin, 5mg/ml streptomycin, 10 mg/ml insulin,
100 mg/ml apo-transferin, 16.1 mg/ml putrescine, 60 ng/ml pro-
gesterone, 30 nM sodium selenite, 0.4 mg/ml triiodo-L-thyro-
nine, 0.4 mg/ml L-thyroxine T4, and 0.1mg/ml BSA) in the
absence or presence of FGF9. Cells were fed twice a week
by replacing half the culture supernatant with fresh media.
Organotypic slice cultures
Organotypic cultures were established and analysed as
described previously (Zhang et al., 2011). Brieﬂy, postnatal
Day 1–2 mouse pups were decapitated and their brains were
Table 1 Summary of FGF9 expression in healthy controls and patients with multiple sclerosis
FGF9 expression
Patient ID Disease type Age Gender GM WM NAWM Lesion rim Lesion core
8-04-1 Control 36 F + + + +
579-91-3 Control 46 M + + + +
28-03-2 Control 42 F + + + +
132-92-4 Control 65 M + + + +
421-91-5 Control 80 F + + +
68-93-4 Control 83 M + + + +
581-96-10D Acute MS 35 M + + + + + + + +
90-09-6 Acute MS 69 F + + + + + + + + +
A01-144 Acute MS 34 F + + + + + + + + +
S403-97 Acute MS 45 M + + + + + + + +
270-99-2 Acute MS 45 M + + + + + + + +
70-93-6 Acute MS 78 M + + + + + + + + + +
Spanien C2 RRMS 40 F + + + + + + + +
39-03-15 Chronic active 67 M + + + - + -
146-01-8 Chronic active 41 M + + + - + -
144-90-3 Chronic active 77 F + + + - + -
67-05-9 Chronic active 34 M + + + - + -
244-94-7 Chronic inactive 81 F + + + - - -
285-81-1 Chronic inactive 78 F + + + - - -
72-83-6 Chronic inactive 64 F + + + - - -
GM = grey matter; WM = white matter; MS = multiple sclerosis; NAWM = normal appearing white matter; RRMS = relapsing remitting multiple sclerosis.
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placed into ice-cold HBSS. Cerebellum and brainstem were cut
into 200–300mm sagittal slices using a McIlwain tissue chop-
per. The slices were placed onto Millicell-CM organotypic
culture inserts (Millipore) in medium containing 50% minimal
essential medium with Earle’s salts, 25% Earle’s Balanced Salt
Solution, 25% heat-inactivated horse serum, GlutaMAX-II
supplemented with penicillin-streptomycin, amphotericin B
(Invitrogen) and 6.5mg/ml glucose (Sigma). Medium was
changed every 2 days. After 10 days in culture, demyelination
was induced by addition of 0.5mg/ml lysophosphatidyl lysole-
cithin (LPC; Sigma) to the medium for 16 h, after which the
slices were transferred back into normal medium 100 ng/ml
FGF9. Cultures were maintained for a further 14 days
and then ﬁxed with 4% paraformaldehyde (PFA) in phos-
phate-buffered saline (PBS) for 1 h while still attached to the
membrane inserts. They were then rinsed in PBS for 10 mins
(three times) and blocked with 3% heat inactivated horse
serum, 2% BSA, and 0.5% TritonTM X-100 in PBS for 1 h.
Slices were incubated with primary antibodies overnight,
washed with PBS once for 10min and then three times for
1 h. Appropriate secondary antibodies (Alexa Fluor,
Invitrogen) were then applied overnight after which the slices
were washed twice for 1 h in PBS and then mounted.
Primary antibodies used for these studies were speciﬁc for:
myelin oligodendrocyte glycoprotein (MOG, 1:500, Abcam),
myelin basic protein (MBP, 1:500, Serotec), proteolipid protein
(PLP, 1:100, AA3 hybridoma supernatant supplied by
S. Barnett), and neuroﬁlament (NFH, 1:50000, EnCor).
Myelination was quantiﬁed by confocal microscopy as
described previously (Zhang et al., 2011) using stacks of
images of myelin (MOG/MBP) and neuroﬁlament immune
labelling obtained at 1 -mm intervals in white matter areas at
40 magniﬁcation. Four slices (four image stacks) were quan-
tiﬁed per treatment/control and the experiment repeated
three times using cultures from different litters of postnatal
Day 1 mice.
Immunofluorescence microscopy
Cultures were ﬁxed with 4% PFA for 20min at room tem-
perature, washed in PBS, permeabilized in 0.5% TritonTM
X-100/PBS for 15min at room temperature, washed with
PBS, and blocked with 1% BSA/10% horse serum/PBS for
1 h at room temperature. Primary antibodies used were:
SMI-31 (1:1500, Abcam), Z2 (anti-MOG, 1:200, clone Z2),
PLP/DM20 (1:100, hybridoma supernatant supplied by S.
Barnett), MBP (1:100, Millipore), O4 (IGKV1D-37, 1:500,
R&D Systems), NG2 (1:200, Millipore), OLIG2 (1:1000,
Millipore), Caspr (1:500, Abcam) and GFAP (1:500, Dako).
These were diluted in blocking buffer and incubations per-
formed either at room temperature for 1 h or overnight at
4C. After gentle washing bound antibodies were visualized
using appropriate combinations of species/isotype speciﬁc
ﬂuorochrome-conjugated secondary antibodies (1:400,
Invitrogen) after incubation at room temperature for 15min.
Cover slips were then washed with PBS followed by distilled
water and mounted with Mowiol 4-88 (Calbiochem) contain-
ing the nuclear stain DAPI. Cell proliferation was analysed
using the Click-iT EdU Alexa Fluor 594 Kit (Invitrogen)
following manufacturer’s instructions, co-stained with DAPI
and other markers and imaged. Images were captured using
an Olympus BX51 ﬂuorescent microscope and Image-Pro
software. For quantitative analysis of neurite density and mye-
lination, 10 random images from each of three coverslips were
taken at 10 magniﬁcation. All experiments were performed
in triplicate providing a total of 270 images per condition for
quantiﬁcation and analysis. Neurite density was quantiﬁed as
described previously (Elliott et al., 2012), myelination and cell
counts were quantiﬁed using CellProﬁler cell image analysis
software (Carpenter et al., 2006). The pipe lines developed
for this study are available at https://github.com/muecs/cp.
In situ hybridization analysis
In situ hybridization studies were carried out using fresh
frozen tissue samples provided by the UK Multiple Sclerosis
Tissue Bank (UK Multicentre Research Ethics Committee,
MREC/02/2/39). Synthetic digoxigenin-labelled riboprobes
(cRNA) were generated from recombinant pCRTMII-Topo
plasmid containing a 606 bp cDNA insert of human FGF9
sequence (5’-2809-3414-3’). Transcription was done from
both sides with either SP6 or T7 RNA polymerase, generating
antisense or sense (control) cRNA probes. In situ hybridization
was performed on cryosections of freshly frozen tissues as
described previously (Schaeren-Wiemers and Gerﬁn-Moser,
1993; Graumann et al., 2003). In situ hybridization signal was
revealed by alkaline phosphatase with BCIP (5-bromo-
4-chloro-30-indolyphosphate) and NBP (nitro-blue tetrazolium)
as substrate. For immunohistochemistry tissue sections were
washed twice with PBS, thereafter sections were treated with
0.6% hydrogen peroxide in methanol for 30min and with
blocking buffer (1% normal donkey serum, 0.1% TritonTM
X-100, 0.05% Tween) for 1 h. Sections were incubated with
the following primary antibodies overnight at 4C: rabbit anti-
OLIG2 (1:500, Millipore), and rabbit anti-GFAP (1:2000,
DakoCytomation). Secondary biotinylated antibodies (Vector
Laboratories, 1:500) were applied for 2 h at room temperature,
followed by ABC complex reagent (Vector Labs) for 30min.
Colour reaction was performed with 3-amino-9-ethylcarba-
zole. Luxol Fast blue and haematoxylin and eosin staining
were performed according to standard protocols.
RNA extraction and microarray
analysis
RNA was extracted from myelinating cultures grown in the
presence or absence of FGF9 (100 ng/ml) for 24 h using the
Qiagen RNeasy Micro kit according to manufacturer’s in-
structions. RNA quality and integrity was checked using the
Agilent Bioanalyzer 6000 Nano LabChip platform. RNA was
then used for microarray expression analysis and quantitative
reverse transcription (qRT)-PCR. The total RNAs were
processed and labelled with biotin using Ambion WT
Expression Kit following the Affymetrix GeneChip WT
Terminal Labeling and Hybridization protocol. The processed
RNAs were hybridized to Affymetrix GeneChip Rat Gene 1.0
ST Arrays using manufacturer’s protocols for using the
Fluidics Station 450. The hybridized arrays were scanned
on the Gene Array Scanner 3000-7G. The data analysis was
carried out in Partek Genomics Suite (version 6.6, Partek)
software. Control and FGF treatment groups were generated
with three replicates per group. This data set
has been deposited in the Gene Expression Omnibus
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database (http://www.ncbi.nlm.nih.gov/geo/ accession number
GSE52753). Probe set level data were normalized using the
GCRMA normalization method and summarized to transcript
cluster level using One-Step Tukey’s Biweight method.
Differential expression analysis was carried out by performing
a two-way ANOVA test on the normalized expression values.
Differentially expressed gene lists were generated based on the
ANOVA linear fold-change4 1.4 (2.639-fold change in
linear scale) at a FDR adjusted P-value of 50.01. The differ-
entially expressed genes were analysed in Partek Pathway for
enriched pathways using the Kegg database for rat.
Quantitative real-time PCR
Changes in expression of selected genes of interest was veriﬁed
using RNA obtained from additional myelinating cultures and
monolayers of neurosphere-derived astrocytes grown in the
presence or absence of FGF9. Following RNA extraction,
cDNA was synthesized using the Qiagen QuantiTect
Reverse Transcription Kit following the manufacturer’s in-
structions. Cycling parameters were as follows: ﬁrst cycle
(DNA wipeout step) 42C for 2min, after adding reverse tran-
scriptase, reaction buffer and primer mix second cycle: 42C
for 20min, then 3min for 95C. Real-time PCR was per-
formed using SYBR Green master mix (Applied
Biosystems), 10 ng cDNA template, 50 pmol/ml of each
primer and distilled water. Primers were designed using the
NCBI nucleotide data base and Primer 3 software (http://bio
tools.umassmed.edu/bioapps/primer3_www.cgi) (Rozen and
Skaletsky, 2000). Primer sequences were checked with
BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi) and were pur-
chased from Sigma or IDT. The reaction was ampliﬁed in an
Applied Biosystems Fast Real-Time PCR System (ABI 7500)
using the following cycle settings: 50C for 5min, 95C for
10min, followed by 40 cycles of 95C for 15 s, 60C for
1min, and a ﬁnal dissociation step at 95C for 15 s. Melt
curve analysis was then performed between 75–99C in 1C
increments. The comparative CT method (or the 2CT
method) (Livak and Schmittgen, 2001; Schmittgen and Livak,
2008) was used to determine differences in gene expression
between FGF9 and control samples. For statistical analysis, a
paired two-sample t-test was used on the mean CT for each
experimental repeat.
Enzyme-linked immunosorbent assay
CCL2 and Hyaluronan concentrations were measured in
supernatants harvested from myelinating cultures (DIV18) or
astrocytes monolayers grown in the presence or absence of
FGF9 for 24 h using mouse/rat CCL2 or Hyaluronan
Quantikine ELISA kits (R&D Systems) according to the manu-
facturer’s instructions. Aggrecanase activity was assayed in
supernatants from myelinating cultures (DIV18) treated with
or without FGF9 for 72 h using an ELISA-based Aggrecanase
Activity Assay Kit (Abnova) following manufacturer’s instruc-
tions. In brief, enzyme activity was assessed by the capacity of
test samples to digest a recombinant fragment of human aggre-
can. This proteolytic cleavage releases an ARGSVIL-peptide,
which is then quantiﬁed by ELISA using appropriate speciﬁc
antibodies.
Results
Tissue damage in multiple sclerosis is
associated with increased expression
of FGF9
We investigated FGF9 expression in post-mortem CNS
tissue from seven control donors and in white matter le-
sions from 14 cases of multiple sclerosis (six acute, one
relapsing remitting, seven chronic; Table 1). In agreement
with previous studies (Todo et al., 1998) FGF9 was ex-
pressed constitutively by neurons and occasionally by glia
and cells associated with the vasculature (Fig. 1A). Neurons
exhibited a punctate pattern of cytoplasmic staining that
was superimposed on a background of extracellular immu-
noreactivity, which may be due to FGF9 in axons and/or
dendrites, or bound to components of the extracellular
matrix. FGF9 immunoreactivity was far less pronounced
in subcortical white matter in which weak staining was
observed in scattered neurons, and less frequently in astro-
cytes and oligodendrocytes (Fig. 1B). This contrasted to the
situation in multiple sclerosis which was associated with a
generalized increase of FGF9 immunoreactivity in white
matter, in particular in active lesions, deﬁned by the abun-
dance of macrophages, containing early myelin degradation
products (Fig. 1C and D). Staining was most pronounced in
oligodendrocytes, although astrocytes and other cells, puta-
tively identiﬁed as OPCs were also immunoreactive
(Fig. 1F). This was not only seen in acute active lesions,
but was also observed, albeit to a lesser extent, at the
rim of slowly expanding white matter lesions from patients
with longstanding progressive disease (Fig. 1 G–I). Normal-
appearing white matter exhibited variable immunoreactiv-
ity in oligodendrocyte-like cells, astrocytes and vessel asso-
ciated cells that were intermediate between that in control
white matter and active lesion areas (Fig. 1E). However,
FGF9 immunoreactivity was minimal in the centre of
slow expanding white matter lesions apart from occasional
weakly staining astrocytes (Fig. 1J). A similar lack of stain-
ing for FGF9 was apparent in chronic inactive lesions
(Fig 1K and L) where immunoreactivity for FGF9 was re-
stricted to occasional axonal spheroids, and cells morpho-
logically consistent with being astrocytes and endothelial
cells (Fig. 1M and N).
The cellular distribution of FGF9 immunoreactivity in
active lesions was then examined in more detail using biop-
sies of early active demyelinating lesions. This conﬁrmed
neurons, GFAP+ astrocytes and occasional NogoA+ oligo-
dendrocytes can all express FGF9 in these lesions, but also
revealed there was substantial variation in the number of
FGF9 immunoreactive glia between cases (Supplementary
Fig. 1). Approximately half of the astrocytes in these lesions
(50.94  0.08 per cent) and surrounding periplaque grey
matter (50.67  0.12 per cent) were immunoreactive for
FGF9. In contrast no FGF9+ reactive astrocytes were
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Figure 1 FGF9 is upregulated in multiple sclerosis lesions. (A) In control grey matter we detected intense extensive granular FGF9
immunoreactivity in the cytoplasm of cortical neurons superimposed on weaker diffuse granular immunoreactivity in the parenchyma. We also
observed weak granular reactivity in some glia cells (arrows) and in association with the vessel wall (arrowhead). (B) Immunoreactivity was less
pronounced in subcortical white matter although we still detected immunoreactivity in neurons (arrows), as well as weak reactivity in occasional
cells with astrocyte morphology (arrowheads). (C and D) Active multiple sclerosis lesion of a patient with acute multiple sclerosis. (C) Myelin is
lost in the plaque (right) in comparison to the periplaque white matter and is taken up by macrophages in the lesions. Immunocytochemical staining
for MOG. (D) Immunocytochemistry for macrophages shows profound infiltration of the lesion (right) and massive microglia activation at the
lesion edge (left). (E) Expression in normal appearing white matter is intermediate between that seen in active lesions and control white matter
and is characterized by variable staining of oligodendrocyte-like cells (arrow), astrocytes (arrowhead) and vessel associated cells (asterisk). (F)
Immunoreactivity for FGF9 was far more pronounced in active lesions compared to control white matter. Strong expression was observed in cells
with oligodendrocyte morphology (arrows), weaker expression in astrocytes (arrowheads) as well as other cell types, possibly OPCs. Rim of an
early active lesion from case of acute multiple sclerosis, disease duration, 2 months. (G and H) Slowly expanding lesions in progressive multiple
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detected in normal-appearing grey matter in the three cases
where this was available. In addition to this pronounced
astrocytic response a small number of NogoA+ cells ex-
pressing FGF9 were also detected in and around these
early demyelinating lesions (Supplementary Fig. 1).
To determine whether glial immunoreactivity for FGF9
was due to de novo synthesis, or uptake from the extracel-
lular milieu we performed in situ hybridization studies in
combination with immunohistochemistry for OLIG2 and
GFAP on fresh frozen tissue sections from active inﬂamma-
tory lesions (Fig. 2A–D, K and L) and chronic inactive
lesions (Fig. 2E–H). This study detected variable, but high
expression of FGF9 in active lesions (Fig. 2C and D),
as well as increased expression associated with the
edge of chronic inactive lesions (Fig. 2G and H)
compared to normal-appearing white matter (Fig. 2I).
Immunohistochemical co-localization studies identiﬁed
Fgf9 mRNA transcripts in some but not all OLIG2+ cells
associated with these lesions (Fig. 2K, arrows), as well as in
a small numbers of GFAP+ astrocytes (Fig. 2L, arrow-
heads). These ﬁndings conﬁrm glial expression of FGF9 is
upregulated at sites of ongoing lesion formation in multiple
sclerosis.
Increased availability of FGF9
compromises (re)myelination in vitro
FGF9 plays important roles in co-ordinating cell prolifer-
ation, differentiation and survival during development, but
its expression is strongly downregulated before birth in the
CNS. Re-expression of FGF9 in the adult CNS might there-
fore be expected to have a signiﬁcant impact on lesion
development in multiple sclerosis; a concept supported by
the ability of FGF9 to suppress myelin protein expression
by OPC (Cohen and Chandross, 2000). We therefore inves-
tigated the effects of adding FGF9 to myelinating cultures
derived from embryonic rat spinal cord by immunoﬂuores-
cence microscopy, a model system that allows us to quan-
tify effects on all stages of the oligodendroglial cell lineage,
as well as myelination and neurite outgrowth. FGF9 in-
hibits myelination in a dose dependent manner (Fig. 3A
and B), 490% inhibition being obtained when FGF9 was
present at a concentration of 100 ng/ml (18–28 DIV)
(Fig. 3B and Supplementary Fig. 2). Failure of myelination
was associated with the appearance of a population of ‘pre-
myelinating’ oligodendrocytes that exhibited a granular
pattern of PLP and MBP immune reactivity in their cytosol.
These cells were observed to extend processes that ended in
large membrane expansions or alternatively, aligned
along and interacted with SMI31+ neurites (Fig. 3A and
Supplementary Fig. 2); an oligodendrocyte phenotype asso-
ciated with chronically demyelinated multiple sclerosis
lesions (Chang et al., 2002).
Inhibition of myelination by FGF9 in these cultures
was accompanied by a signiﬁcant increase in the
number of OLIG2+ , NG2+ and PLP+ cells (Fig. 3C and
Supplementary Fig. 3); an effect associated with prolifer-
ation as demonstrated by incorporation of EdU (5-ethy-
nyl-2-deoxyuridine) into cells expressing oligodendrocyte
lineage-speciﬁc markers (Fig. 3D). Incorporation of EdU
was increased 3-fold in OLIG2+ cells, 4–5-fold in O4+
cells and almost 10-fold in PLP+ cells. This effect of
FGF9 on the oligodendroglial lineage was reminiscent of
that reported for FGF2, a well-characterized OPC mitogen
that inhibits OPC differentiation by limiting their ability to
drop out of cell cycle. We therefore performed experiments
to determine whether this represents a generalized response
to FGF signal transduction in this culture system. However
screening nine family members revealed this is not the case.
Only FGF9 and to a lesser extent FGF2 stimulated an in-
crease in OLIG2+ cell numbers while at the same time in-
hibiting myelination (Supplementary Fig. 3C and D).
We then went on to explore whether inhibition of mye-
lination by FGF9 in this culture system was dependent on
maintaining OPCs in cell cycle using AraC to eliminate
proliferating cells (Fig. 3E and Supplementary Fig. 3).
Control experiments revealed that although treatment
with AraC from 18 to 28 DIV signiﬁcantly reduced cell
proliferation, this had no effect on myelination per se; an
observation indicating myelination during this period is
performed by a pre-existing pool of non-proliferating
OPCs. AraC also eliminated the proliferative response
induced by FGF9; however, this failed to abrogate the
effect of FGF9 on myelination demonstrating this is inde-
pendent of its ability to act as a glial mitogen (Fig. 3E). In
contrast to these marked effects on cells of the oligodendro-
cyte lineage and myelination FGF9 had no effect on
neurite density as determined by SMI31 immune reactivity
Figure 1 Continued
sclerosis are defined by myelin loss and the presence of some macrophages at the lesion border with myelin degradation products (G); there is
massive microglia activation at the lesions edge and some immunoreactive cells have macrophage morphology (H). (I) FGF9 immunoreactivity is
increased at the edge of slowly expanding white matter lesions from cases of progressive disease. In this case immunoreactivity is associated with
axonal spheroids (arrows) and glia (arrowhead). Rim of a slowly expanding lesion from a case of primary progressive multiple sclerosis. (J) The
centre of chronic active lesions show very limited astrocytic immunoreactivity for FGF9. (K and L) Inactive lesions show myelin loss with a sharp
border towards the periplaque white matter (PPWM) (K) and no immunoreactivity for macrophage antigens (e.g. CD68) within or around the
lesion (L). Immunoreactivity for FGF9 across inactive chronic lesions is far lower than in control white matter as seen at the lesion rim (M) where
immunoreactivity is associated with an axonal spheroid (arrow) as well as weaker and variable staining of glia (arrowheads). In the centre of the
same lesion (N) weak immunoreactivity is seen associated with a single cell, morphologically consistent with an endothelial cell. (K–N) Inactive
lesion from a case of secondary progressive multiple sclerosis with a duration of 435 years. Scale bar in all panels corresponds to 20 mm.
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Figure 2 In active lesions FGF9 is expressed by cells of the oligodendrocyte lineage. In situ hybridization (ISH) was performed on
fresh frozen post-mortem multiple sclerosis brain tissue with active and chronic active white matter lesions identified by Luxol Fast blue (LFB) (A
and E, respectively). B and F show the corresponding haematoxylin and eosin (HE) staining of consecutive tissue sections. In situ hybridization for
FGF9 transcripts show high level of expression within active lesion (C and D, higher magnification), increased expression in the edge of chronic
active lesions (G and H, higher magnification), and high expression in cerebral cortex (I), whereas in normal-appearing white matter (NAWM)
FGF9 is expressed at low levels (H and I). Immunohistochemical colocalization detects FGF9 transcripts mainly in OLIG2-positive cells (K,
arrows), but also in a small number of GFAP-positive cells (L, arrows) although most GFAP-positive cells were negative (arrowhead). Scale
bar = 500 mm in A–C, E–G and I; 100 mm in D and H; and 25mm in K and L.
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Figure 3 FGF9 inhibits myelination and expands OPC numbers in vitro. Oligodendrocytes in untreated cultures myelinate multiple
axons (A); MBP (red) reactivity is predominantly associated with myelin sheaths, whereas PLP (green) immunoreactivity is also present in the
oligodendrocyte cell body. Treatment with 100 ng/ml FGF9 from 18–28 DIV is associated with the appearance of multi-branched oligodendrocytes
that exhibit a granular staining pattern for MBP and PLP in the cell body and fail to generate myelin sheaths. MBP, red; PLP, green; SMI31, blue. Scale
bar = 20mm. Inhibition of myelination by FGF9 in these cultures is dose-dependent (B); myelination was quantified using a MOG-specific antibody
as described in the text. This treatment is associated with increased numbers of OLIG2 + (P5 0.001), NG2 + (P5 0.01) and AA3 + (P5 0.01)
cells. There was also a trend for O4 + cell numbers to increase, but this did not reach significance (P = 0.055) (C). This increase in OPC numbers
was due to proliferation as demonstrated by the presence of increased numbers of OLIG2, O4 and AA3 (PLP/DM20) immunoreactive cells
labelled with EdU (DIV 18–22) (D). However, the ability of FGF9 to inhibit myelination is independent of this proliferative response as inhibition of
proliferation by cytosine arabinoside (AraC, 20 mM) was unable to abrogate inhibition of myelination by FGF9 (E). Data are presented as
mean  SEM obtained from a minimum of three experiments; *P5 0.05; **P5 0.01; ***P5 0.001.
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(100 ng/ml; DIV 18–28; Control 77.87  3.11; FGF9 trea-
ted 77.75  5.09; percent SMI31+ pixels per ﬁeld).
These experiments demonstrate FGF9 inhibits myelin-
ation in a developmental setting, but it remained unclear
whether it would also compromise remyelination. To ex-
plore this further we addressed this question by monitoring
the effect of FGF9 on remyelination in cerebellar slice cul-
tures demyelinated by treatment with LPC (Fig. 4). Analysis
of cultures 14 days after exposure to LPC revealed remye-
lination was signiﬁcantly reduced in the presence of FGF9
compared to demyelinated cultures that were not exposed
to this factor (P5 0.01) (Fig. 4).
FGF9 is a stage dependent mitogen
for OPCs
The observation that FGF9 induced OPC proliferation in
myelinating cultures was unexpected as previous studies
reported FGF9 is not a mitogen for puriﬁed OPCs (Fortin
et al., 2005). However, as OPCs differentiate into mature
oligodendrocytes they sequentially express different high
afﬁnity receptors for FGF9. Receptor expression changes
from FGFR3 in OPCs to FGFR2 in mature myelinating
oligodendrocytes; activation of the latter by FGF9 trigger-
ing changes in process outgrowth without affecting expres-
sion of myelin proteins (Fortin et al., 2005). These results
were however obtained after short term (48 h) exposure of
either early or highly differentiated progenitors to FGF9.
This prompted us to investigate the effect of continuous
exposure to FGF9 on OPC differentiation. Using A2B5+
progenitor cells immunopuriﬁed from the neonatal CNS
we conﬁrmed FGF9 is not a mitogen for OPCs during
their initial stages of differentiation in Sato’s medium
(DIV 1–3; Fig. 5A). However, they subsequently become
responsive to its mitogenic potential as later exposure
(DIV 4–7) doubles incorporation of EdU (Fig. 5A). This
proliferative response was associated with inhibition of dif-
ferentiation as demonstrated by analysis of cultures con-
tinuously exposed to FGF9 for 7 days; the number of
OPCs expressing O4, PLP and MOG being reduced by
30%, 86% and 490%, respectively (Fig. 5B and C).
These results suggest a direct effect of FGF9 on cells of
the oligodendrocyte lineage would account for its ability
to inhibit myelination. However, our data question the
validity of this supposition. Speciﬁcally, inhibition of mye-
lination by FGF9 in the far more complex cellular environ-
ment of our myelinating cultures was neither dependent on
its mitogenic potential (Fig. 3E), nor was it associated with
a net decrease in O4+ or PLP+ cell numbers (Fig. 3C). In
fact the converse was true, FGF9 increased the absolute
number of O4+ and PLP+ cells in these cultures by 37%
and 68%, respectively (Fig. 3C). We reasoned this dichot-
omy could be explained by an off target effect of FGF9 that
compensated for any direct effect of FGF9 on OPC differ-
entiation, but which at the same time might also adversely
affect myelination. The most likely candidates being
astrocytes as they constitutively express FGFR3 (Young
et al., 2010), a preferred high afﬁnity receptor for FGF9
(Goetz and Mohammadi, 2013).
To test this hypothesis we grew myelinating cultures
(18–28 DIV) in the presence of supernatants harvested
from naı¨ve or FGF9 treated neurosphere-derived astrocytes
in the presence or absence of a neutralizing antibody to
eliminate any direct effect of residual FGF9. Control experi-
ments established this antibody had no deleterious effect on
myelination per se, but completely neutralized the ability of
FGF9 to inhibit myelination (Fig. 5D). However, the inhibi-
tory activity of supernatants harvested from FGF9-treated
astrocytes could not be abrogated by this FGF9-speciﬁc
antibody demonstrating inhibition of myelination is domi-
nated by mechanisms involving one or more astrocyte-
derived factors (Fig. 5D).
FGF9 activates immune and
neurobiological pathways relevant for
lesion formation
To identify mechanisms by which FGF9 inhibits myelin-
ation we performed a microarray analysis on myelinating
cultures (DIV 18) grown in the presence or absence of
FGF9 for 24 h. This identiﬁed 3262 transcripts differen-
tially regulated by FGF9 (1752 upregulated, 1510 down-
regulated; fold-change4 1.4; P50.01; Fig. 6 and
Table 2). Pathway enrichment analysis using the
731 most differentially regulated transcripts (fold
change4 2.2; P5 0.01) identiﬁed 17 enriched pathways
(P5 0.05; Fisher’s Exact Test; Supplementary Table 1).
The most highly enriched was the cell cycle pathway, an
observation that reﬂects the proliferative response to FGF9.
However three of the four next most enriched pathways are
associated with both neurobiological and immune functions
(transforming growth factor beta signalling, P = 0.00025;
cytokine-cytokine receptor interaction, P = 0.00098; Jak-
STAT signalling, P = 0.0048); an observation suggesting
that in addition to any effect on remyelination increased
availability of FGF9 may also modulate immune function
within the CNS. This hypothesis is supported by the obser-
vation that FGF9 increased expression of a cluster of ‘pro-
inﬂammatory’ genes (Ccl7, Cd93, Cd63, Ccl2, Il1rap,
Tnfrsf10b and Il1r1) more commonly discussed in the con-
text of innate immunity rather than their neurobiological
effects. The relative magnitude of this effect is apparent
when signiﬁcance (log10 P) is plotted against fold-change
in expression which highlights the profound effects of
FGF9 on expression of Ccl7 (ranking 1; 31-fold increase),
Cd93 (ranking 4; 17-fold increase), Il1rap (ranking 55;
5-fold increase) and Ccl2 (ranking 56; 5-fold increase)
(Fig. 6 and Table 2). This raises the possibility that in add-
ition to its ability to inhibit (re)myelination, FGF9 may also
promote a pro-inﬂammatory environment in the CNS, a
combination of effects predicted to exacerbate axonal
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injury and loss in multiple sclerosis lesions (Franklin et al.,
2012).
In addition to this ‘pro-inﬂammatory’ effect FGF9 modu-
lated expression of multiple genes associated with pathways
implicated previously in failure of remyelination. These
include changes indicative of altered hyaluronan/CD44
signalling (Has2, Cd44; Tuohy et al., 2004; Back et al.,
2005; Sloane et al., 2010; Bugiani et al., 2013), integrin/
ﬁbronectin associated effects (Itga5, Fn1; Stoffels et al.,
2013), as well as changes predicted to affect availability
of soluble factors known to support OPC migration, differ-
entiation and/or survival (Stark and Cross, 2006) such as
Cntf (Stankoff et al., 2002), Cxcl12 (Patel et al., 2010) and
Fgf2 (Clemente et al., 2011).
To identify which of these pathways might contribute to
inhibition of myelination we ﬁrst validated selected
Figure 4 FGF9 compromises remyelination in organotypic slices. Cerebellar slices from post-natal Day 2 mouse pups were cultured for
10 days and then demyelinated using LPC for 16 h. Cultures were then allowed to remyelinate over the next 14 days in the presence or absence of
FGF9 (100 ng/ml) after which remyelination was assessed using antibodies specific for MOG and PLP to label myelin, and neurofilament (NFH) to
label axons. Confocal immunofluorescence microscopy shows treatment with FGF9 leads to less remyelination (A) as demonstrated by the
reduction in MOG + internodes (red) and PLP + internodes (green) encasing NFH + axons (blue). Scale bar = 10mm. Remyelination was quantified
using image analysis to define co-localization of staining for myelin (PLP + or MOG + ) and axons (NFH + ) (B)—a quantification of myelinated
internodes we term the remyelination index (amount of myelin/axon). Irrespective of the antibody used to identify myelinated internodes,
treatment with FGF9 (F) reduced remyelination compared to untreated cultures (C). Mean  SEM (n = 3, at least six slices per experiment;
***P5 0.001; **P5 0.01.
1886 | BRAIN 2015: 138; 1875–1893 M. Lindner et al.
candidates by quantitative PCR using reverse-transcribed
mRNA isolated from myelinating cultures and astrocyte
monolayers cultured for 24 h in the presence or absence of
FGF9. This strategy revealed FGF9 upregulated astrocytic
expression of a number of proteases in particular
ADAMTS1, ADAMTS7 and MMP3 (Table 2 and
Supplementary Table 2). These mediate a wide range of bio-
logical processes including extracellular matrix remodelling
which led us to speculate they may adversely affect (re)mye-
lination. This hypothesis received further support when
assays using aggrecan as a ‘global’ substrate for ADAMTS
and MMP family members revealed FGF9 signiﬁcantly
increased aggrecanase activity in supernatants harvested
from myelinating cultures (Fig. 6B). To determine whether
this protease activity was actively involved in mediating in-
hibition of myelination we used a cocktail of physiological
protease inhibitors (TIMP1, TIMP2 and TIMP3) known to
inhibit a wide range of ADAMTS andMMP family members.
The inhibitors had no effect on myelination per se but abro-
gated the inhibitory effect of FGF9 which was reduced by
37% (n = 3; FGF9 versus untreated control, 78.2  5.8%
inhibition, P5 0.01; FGF9 + TIMP versus untreated control,
49.1  11.8 inhibition, not signiﬁcant) (Fig. 6C). Induction of
TIMP-sensitive proteases therefore makes a signiﬁcant con-
tribution to the mechanisms by which FGF9 inhibits myelin-
ation in this culture system.
Why this cocktail of inhibitors fails to completely abro-
gate the effect of FGF9 remains unclear. This may be due
to incomplete inhibition of the relevant proteases, or alter-
natively involvement of other factors such as chemokines
(Ccl2, Ccl7), IL6/gp130 cytokine family members (Il11, Lif,
Cntf) and growth factors (Hbegf, Vgf, Hgf). To explore this
Figure 5 FGF9 inhibits OPC differentiation directly and induces secretion of myelination-inhibiting factors by astrocytes.
Proliferation of immunopurified A2B5+ OPCs cultured in the presence or absence of FGF9. FGF9 is not initially an OPC mitogen (DIV 1–3), but
progenitors become responsive as they differentiate (DIV 4–7) (A). This proliferative response is associated with inhibition of OPC differentiation
assessed using three stage specific markers (O4, PLP and MOG) (B and C). B provides representative images demonstrating the effect on
expression of PLP and MOG. Scale bar = 100 mm. Supernatants from FGF9 treated and untreated neurosphere-derived astrocytes were harvested
and added to myelinating cultures in the presence or absence of a neutralizing anti-FGF9 antibody (10mg/ml) from 18 to 28 DIV (D). Quantifying
PLP + myelination reveals the FGF9-specific antibody neutralized the ability of FGF9 to inhibit myelination, but failed to block inhibitory activity
present in supernatants harvested from FGF9-treated astrocytes. (A, C and D) Data represent means  SEM from at least three independent
experiments; ***P5 0.001; **P5 0.01; *P5 0.05, n.s. = not significant.
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possibility we screened a number of soluble factors that our
data suggest are expressed by astrocytes. For example our
validation strategy indicates CCL2 is derived primarily
from astrocytes, whereas Has2 is upregulated in some
other cell type (Supplementary Table 2). To validate this
interpretation we determined the concentrations of CCL2
and hyaluronic acid (a surrogate marker for increased
HAS2 activity) in supernatants harvested from myelinating
cultures and astrocyte monolayers grown in the presence or
absence of FGF9 (Supplementary Fig. 4). Basal concentra-
tions of CCL2 were similar in myelinating cultures and
astrocyte monolayers and upregulated to similar extents,
16 - and 14-fold, respectively, conﬁrming astrocytes were
a major source of FGF9-induced CCL2 production. In con-
trast basal and induced levels of hyaluronic acid were far
higher in supernatants harvested from myelinating cultures
than astrocyte monolayers indicating astrocytes are not the
major cellular source of hyaluronic acid in myelinating cul-
tures. Screening selected candidates such as CCL2, CCL7
and IL11 has, however, as yet failed to identify any that
replicate the effects of FGF9. Similarly CNTF, which is
downregulated by FGF9, was unable to abrogate the effects
of FGF9 (Supplementary Fig. 4).
Discussion
Signal transduction by members of the FGF family inﬂu-
ences OPC proliferation, survival and differentiation in the
rodent CNS, observations that stimulated speculation aber-
rant FGF expression may play a role in the pathogenesis of
multiple sclerosis (McKinnon et al., 1990; Bansal and
Pfeiffer, 1994; Goddard et al., 2001; Oh et al., 2003;
Fortin et al., 2005; Tobin et al., 2011; Furusho et al.,
2011, 2012; Mohan et al., 2014). This concept has until
now focused on FGF2, a well-characterized OPC mitogen
(McKinnon et al., 1990) that is over expressed in multiple
sclerosis tissues (Sarchielli et al., 2008; Clemente et al.,
Figure 6 Transcriptional profiling of the effects of FGF9 in myelinating cultures. (A) Volcano plot of fold-change versus log10
significance reveals FGF9 upregulated a cluster of pro-inflammatory genes (dark blue) including Ccl7 and Ccl2; induced expression changes
indicative of extracellular matrix remodelling (red); modulated the relative expression of IL6/gp130 gene family members (light blue) and uniformly
reduced expression of myelin associated genes. (B) Aggrecanase activity was assayed in supernatants from myelinating cultures grown in the
presence or absence of FGF9 for 72 h. Cell culture supernatants protolytically cleave a recombinant aggrecan substrate into ARGSVIL-peptide
which is then measured by ELISA. Data represent the mean  SEM of seven independent experiments, *P5 0.05. (C) Myelinating cultures were
treated with FGF9 for 10 days in the absence or presence of tissue inhibitors of metalloproteinases (TIMP1, TIMP2 and TIMP3; each at 1 mg/ml)
after which myelination was quantified, as described in the text. This cocktail of TIMPS had no effect on basal levels of myelination, but abrogated
inhibition of myelination by FGF9. Representative data (mean  SEM) from one of three independent experiments.
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2011) and which acts as a negative regulator of remyelina-
tion in the adult CNS (Tobin et al., 2011). We now report
expression of FGF9 is also upregulated in multiple sclerosis
lesions and provide evidence this will result in a complex
cellular response predicted to exacerbate disease activity in
patients.
Our data demonstrate expression of FGF9 is not only upre-
gulated in early active lesions, but remains elevated at sites of
ongoing tissue damage in patients with longstanding progres-
sive disease. At these sites induction of FGF9 was observed in
GFAP+ astrocytes, OLIG2+ and occasionally more mature
NOGO-A+ oligodendrocytes, a complex cellular response con-
sistently associated with a background of diffuse extracellular
immunoreactivity. The latter is attributed to FGF9 binding to
heparin sulphate proteoglycans (HSPG) in the extracellular
matrix, a property that sequesters its direct biological effects
to the immediate vicinity of its site of synthesis (Harada et al.,
2009; Goetz and Mohammadi, 2013). FGF9 expression was
far lower in adjacent normal-appearing white matter and lar-
gely absent in chronically demyelinated inactive lesions, a pat-
tern that suggests induction represents a localised glial response
to ongoing tissue damage. More detailed analysis of lesion
biopsies revealed considerable variation in the number of
FGF9 immunoreactive glia associated with early active lesions.
Whether this variation in glial expression of FGF9 is due
to differences in age or anatomical localization of lesions is
currently under investigation, as are the molecular mechan-
isms responsible for its induction. Preliminary studies sug-
gest this is not simply a glial response to T cell mediated
inﬂammation, as increased expression of FGF9 is not
observed in animals with experimental autoimmune en-
cephalomyelitis. Moreover, FGF9 expression is increased
at the active rim of slowly expanding white matter lesions
in patients with long standing progressive disease, a site
associated with minimal recruitment of lymphocytes from
the periphery (Lassmann et al., 2012). One factor that
might contribute to this response is decreased expression
of Smad-interacting protein-1 (now known as ZEB2),
which suppresses neuronal expression of FGF9 during cor-
tical development (Seuntjens et al., 2009). Intriguingly, this
transcription factor is expressed by oligodendrocytes and
plays an essential role in CNS myelination (Weng et al.,
2012), an observation that raises the possibility ZEB2
may also inﬂuence oligodendroglial expression of FGF9.
Analysis of the effects of FGF9 in vitro revealed it not
only inhibited myelination/remyelination, but also induced
expression of the pro-inﬂammatory chemokines Ccl2 and
Ccl7. These pleiotropic effects are mediated by high afﬁnity
receptors for FGF9 (FGFR2, FGFR3; Hecht et al., 1995)
that are expressed by many cells in the CNS including
astrocytes (Reuss et al., 2000; Young et al., 2010), as
well as OPCs and myelinating oligodendrocytes (Fortin
et al., 2005). However, although FGF9 was found to in-
hibit the differentiation of isolated OPC into mature oligo-
dendrocytes, this direct effect does not seem to be
responsible for its ability to inhibit of myelination in the
far more complex, multicellular environment of our myeli-
nating cultures.
We were initially perplexed by this observation as previ-
ous studies failed to report any signiﬁcant effect of FGF9
on OPC proliferation or differentiation (Fortin et al.,
Table 2 Genes shown in the volcano plot
# Gene Fold-change P-value Rank
Pro-inflammatory genes
1 *Ccl7 31.03 7.28  1020 1
2 Cd93 17.48 9.60  1017 4
3 Cd63 8.89 7.42  1017 21
4 Il1rap 4.96 1.32  1018 55
5 *Ccl2 4.96 6.46  1017 56
6 Tnfrsf10b 3.19 2.50  1011 110
7 Il1r1 2.04 1.88  1007 426
8 *Cxcl12 1.59 4.40  1003 28 267
Extracellular matrix genes
9 *Adamts1 19.83 1.60  1016 2
10 Itga5 7.04 1.64  1015 29
11 Igfbp3 6.67 4.37  1017 32
12 Adam12 5.33 2.30  1010 49
13 *Has2 5.09 2.89  1011 51
14 *Adamts7 4.74 2.50  1014 60
15 Chst3 3.59 4.96  1016 88
16 Adamts9 2.93 4.20  1010 131
17 Adamts14 2.84 5.26  1018 143
18 *Cd44 2.65 2.61  1016 179
19 Fn1 2.13 4.42  1006 371
20 Adamts4 2.08 2.47  1009 397
21 Lama5 1.71 1.63  1007 778
22 Mmp15 1.67 4.30  1012 833
23 *Mmp3 1.65 4.00  1005 860
24 Itgb1 1.58 6.28  1011 1062
25 Itgb8 1.54 1.47  1013 1184
26 Icam1 1.44 6.36  1006 1554
27 Mmp11 1.43 1.11  1003 1627
IL6/Gp130 family genes
28 *Clcf1 14.19 5.92  1020 6
29 *Il11 9.26 1.47  1015 19
30 *Lif 5.70 3.42  1011 42
31 Osmr 2.26 5.20  1013 302
32 Il6 1.26 7.39  1003 3104
33 Stat2 2.11 5.91  1010 28 775
34 *Cntf 2.42 4.04  1011 28 895
Myelin genes
35 Plp1 1.39 1.18  1011 27 534
36 Cnp 1.51 3.51  1010 28 057
37 Opalin 1.60 2.61  1005 28 296
38 *Mog 1.69 3.45  1008 28 414
39 Omg 1.70 1.14  1012 28 443
40 *Mbp 1.72 6.02  1009 28 479
41 *Mag 1.74 8.45  1009 28 497
42 Mobp 2.93 4.52  1012 29 021
Other genes
43 *Hbegf 10.86 7.99  1017 11
44 *Vgf 4.56 2.58  1012 65
45 *Fgf2 1.55 7.14  1009 1140
46 *Hgf 8.02 1.39  1020 19 788
Highest rank corresponds to highest fold-change.
*Genes validated by quantitative PCR.
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2005). However, this earlier study only examined short
term responses of early OPCs or mature oligodendrocytes,
whilst in the current study we examined the effect of con-
tinuous exposure to FGF9 on differentiating A2B5+ pro-
genitors over a period of 7 days. This revealed that as they
differentiate these cells enter a stage in which they become
FGF9 sensitive; as demonstrated by their proliferative re-
sponse that may reﬂect a developmental switch in expres-
sion of FGFR3 to FGFR2 (Fortin et al., 2005). Re-entry of
these isolated progenitors into cell cycle was associated
with inhibition of differentiation and a corresponding de-
crease in the appearance of PLP+ OPCs. However the re-
verse was observed when we explored the effects of FGF9
on the oligodendrocyte lineage in myelinating cultures. In
this complex cellular environment FGF9 still acts as an
OPC mitogen as demonstrated by EdU labelling studies,
but in this case this results in a net increase in PLP+
cells. This dichotomy can be explained by off-target effects
of FGF9 on other cells in the culture that override or com-
pensate for its direct effect on the differentiation of early
progenitors. Possible candidates are astrocyte-derived ‘pro-
myelinating’ factors such as IL11 and LIF (Ishibashi et al.,
2006; Zhang et al., 2006) that we found are upregulated
by FGF9 in myelinating cultures. However despite any
potential beneﬁt this may provide, myelination was none-
theless inhibited by an astrocyte-dependent mechanism that
inhibits differentiation MBP/PLP+ precursors into mature
myelination-competent oligodendrocytes.
Transcriptional proﬁling revealed inhibition of myelin-
ation was associated with changes in gene expression af-
fecting several pathways previously implicated as causes of
remyelination failure in multiple sclerosis, in particular
those involving interactions with components of the extra-
cellular matrix (e.g. Adamts1, Has2, Chst3, Adamst9, Fn1,
Cd44, Mmp3, Mmp11, Mmp15). These include CD44/hya-
luronan signalling (Tuohy et al., 2004; Back et al., 2005;
Chang et al., 2012; Bugiani et al., 2013), as well as effects
associated with increased availability of chondroitin sul-
phate proteoglycans (Siebert et al., 2011) and ﬁbronectin
(Stoffels et al., 2013). The latter is of interest as ﬁbronectin
inhibits myelination via an integrin–dependent mechanism
that disrupts vesicular trafﬁc to sites of myelin assembly
(Maier et al., 2005; Siskova´ et al., 2006, 2009); an effect
that may contribute to the appearance of granular staining
for MBP and PLP in the cytosol of oligodendrocytes in
FGF9-treated myelinating cultures. It was also noted that
processes extended by these cells appear to be able to inter-
act with neurites but nonetheless fail to myelinate; a pheno-
type reminiscent of that seen in chronically demyelinated
multiple sclerosis lesions (Chang et al., 2002).
These effects were accompanied by increased expression of
protease families implicated in extracellular matrix remodel-
ling (Howell and Gottschall, 2012; Lau et al., 2013), in
particular a disintegrin and metalloproteinase with throm-
bospondin type 1 motif (ADAMTS) family members 1, 4,
7, 9 and 14; matrix metalloproteinase (MMP) family mem-
bers 3, 11 and 15 and disintegrin and metalloproteinase
domain (ADAM) 12. The activity of these metalloprotei-
nases is regulated to differing extents by tissue inhibitors
of metalloproteinases (TIMPs), a family of four physiological
protease inhibitors. This was exploited to demonstrate
increased expression/activity of TIMP-sensitive proteases
contributes to the inhibitory effect of FGF9 on myelination.
Further studies are now required to determine the relative
contribution of speciﬁc proteases and their pathophysio-
logical substrates. Our inability to completely abrogate the
inhibitory effect of FGF9 on myelination using a combin-
ation of TIMPs may indicate additional pathways contribute
to its downstream effects on myelination. However, it should
be noted that the inhibitor cocktail used in this study only
inhibited aggrecanase activity in cell culture supernatants by
50% raising the possibility more complete inhibition could
fully abrogate the effect of FGF9. Moreover, screening other
potential candidates has as yet failed to identify any that
replicate the inhibitory activity of FGF9 (Supplementary
Fig. 4).
In addition to transcriptional changes indicative of extra-
cellular matrix remodelling, our micro array study revealed
FGF9 enhanced expression of a cluster of ‘pro-inﬂamma-
tory’ genes, in particular Ccl7 and Ccl2; the latter being
validated at the protein level. These chemokines are ex-
pressed in multiple sclerosis lesions where they are thought
to be involved in recruiting macrophages and microglia
(McManus et al., 1998). This ability of FGF9 to induce
this ‘pro-inﬂammatory’ response and at the same time in-
hibit remyelination has major implications with respect to
its role in disease pathogenesis. Traditionally multiple scler-
osis is viewed as an inﬂammatory disease driven by auto-
immune response in the periphery, but immunomodulatory
treatments that target this response and disease activity in
relapsing-remitting multiple sclerosis generally fail to bene-
ﬁt patients with progressive forms of the disease. These
immune modulatory treatments are thought to fail because
accumulation of disability in these patients is driven by
inﬂammatory mechanisms sequestered within the CNS
that are largely independent of T cell recruitment from
the periphery (Lassmann et al., 2012). Our data suggest
glial expression of FGF9 will contribute to this scenario
by virtue of its effects on astrocytes that inhibit remyelina-
tion and generate a pro-inﬂammatory chemokine response;
a combination of effects predicted to exacerbate axonal loss
while simultaneously recruiting more inﬂammatory cells
into the developing lesion (Franklin et al., 2012). In sum-
mary our data identify FGF signalling in astrocytes as a
novel target for both regenerative and anti-inﬂammatory
therapies in multiple sclerosis.
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